Learning Objectives:

1. Review the history of discovery of PCSK9 and the first inhibitors.

2. Understand siRNA approaches to PCSK9 anatagonism.

3. Become aware of the pipeline of anti-PCSK9 therapies.

Session date: 
05/13/2022 - 12:00pm to 1:00pm CDT
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Michael Shapiro, DO